Dexcom reported first-quarter results that topped Wall Street expectations and reiterated its full-year revenue outlook, but its shares moved lower in after-hours trading.
The medical device company recorded quarterly revenue of $1.19 billion, a 15% increase from the year-ago period and slightly above the analyst consensus estimate of $1.18 billion. On the profitability front, adjusted earnings reached $0.56 per share, surpassing the expected $0.47 per share.
Guidance and market response
Management confirmed full-year revenue guidance in a range of $5.16 billion to $5.25 billion. Analysts covering the company had forecast revenue of $5.23 billion for the year. Following the release, Dexcom's stock declined 4.3% in after-hours trading.
Product developments and clinical findings
During the quarter, Dexcom expanded the U.S. rollout of its G7 15 Day sensor. The company also added meal-logging capabilities to its Stelo platform, enhancing patient tracking and user engagement features. In addition, Dexcom published clinical data showing benefits for people with type 2 diabetes who are not using insulin.
Demand environment
Dexcom said demand for its continuous glucose monitoring - or CGM - devices remained healthy. The firm emphasized that its finger-prick-free technology has continued to gain traction as awareness of diabetes care grows and as insurance coverage expands, supporting uptake.
The quarter combined solid top-line growth and a profit beat with a reaffirmed guidance range, while investors digested product progress and clinical evidence supporting broader usage. The after-hours share decline reflects market sensitivity to execution, guidance framing, and near-term investor expectations.